growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
=== Epidermal-dermal signaling === Silicone-related products can reduce the growth factor production of fibroblasts in hypertrophic scars and keloids. However, the relevance is unclear as silicone products do not have direct contact with dermal fibroblasts but with the epidermis only. Possible relevance may be due to the initiation of a signaling cascade by the epidermis. Through the signaling cascade, the epidermis regulates dermal fibroblast extracellular matrix production. Delayed epithelialization, which raises the risk of hypertrophic scar formation, is less likely to happen. A negative static electric charge is formed by friction between the silicone gel sheet and the skin. The charge induces collagen realignment, aiding the elimination of the scar. Moreover, the negative electric field leads to the polarization of scar tissues and thus scar shrinkage.
Ring or Double arcuate scotoma: Two arcuate scotomas join to form a Ring or Double arcuate scotoma. This defect is seen in advanced stages of glaucoma. Roenne's central nasal step: It is created when two arcuate scotomas run in different arcs to form a right-angled defect. This is also seen in advanced stages of glaucoma. Peripheral field defects: Peripheral field defects may occur in early or late stages of glaucoma. Roenne's peripheral nasal steps occur due to contraction of peripheral isopter. Tubular vision: Since macular fibers are the most resistant to glaucomatous damage, the central vision remains unaffected until the end stages of glaucoma. Tubular vision or Tunnel vision is the loss of peripheral vision with retention of central vision, resulting in a constricted circular tunnel-like field of vision. It is seen in the end stages of glaucoma. Retinitis pigmentosa is another disease that causes tubular vision. Temporal island of vision: It is also seen in the end stages of glaucoma. The temporal islands lie outside of the central 24 to 30° visual field, so it may not be visible with standard central field measurements done in glaucoma.
=== Oxidative stress === Oxidative stress causes the accumulation of reactive oxygen species (ROS), resulting in oxidative damage to DNA, proteins involved in cellular repair, and lipids that support the skin barrier. Oxidative stress can hinder the fibroblasts' collagen production, endothelial cell angiogenesis, and keratinocytes' re-epithelialization. The result of oxidative stress is a state of cellular senescence, where cells secrete pro-inflammatory factors and are unable to divide. Senescent cells signal to immune cells, perpetuating a non-resolving wound that can develop into an ulcer.
Although rubidium is more abundant in Earth's crust than caesium, the limited applications and the lack of a mineral rich in rubidium limits the production of rubidium compounds to 2 to 4 tonnes per year. Several methods are available for separating potassium, rubidium, and caesium. The fractional crystallization of a rubidium and caesium alum (Cs,Rb)Al(SO4)2·12H2O yields after 30 subsequent steps pure rubidium alum. Two other methods are reported, the chlorostannate process and the ferrocyanide process. For several years in the 1950s and 1960s, a by-product of potassium production called Alkarb was a main source for rubidium. Alkarb contained 21% rubidium, with the rest being potassium and a small amount of caesium. Today the largest producers of caesium produce rubidium as a by-product from pollucite.
Sources: en.wikipedia.org
=== Aerial capabilities === The Houthis exert partial control over the Yemeni Air Force, and possess key air bases such as Al-Dailami and Al Hudaydah. The Houthi air force consists of a single Northrop F-5 fighter jet, which was seized from the Yemeni government. The group also flew a Soviet-era Mikoyan MiG-29 during a military parade over Sanaa in 2023. They also operate Mil Mi-17 helicopters seized during the civil war.
The sponsor designs the trial in coordination with a panel of expert clinical investigators, including what alternative or existing treatments to compare to the new drug and what type(s) of patients might benefit. If the sponsor cannot obtain enough test subjects at one location investigators at other locations are recruited to join the study. During the trial, investigators recruit subjects with the predetermined characteristics, administer the treatment(s) and collect data on the subjects' health for a defined time period. Data include measurements such as vital signs, concentration of the study drug in the blood or tissues, changes to symptoms, and whether improvement or worsening of the condition targeted by the study drug occurs. The researchers send the data to the trial sponsor, who then analyzes the pooled data using statistical tests. Examples of clinical trial goals include assessing the safety and relative effectiveness of a medication or device:
β-Endorphin (beta-endorphin) is an endogenous opioid neuropeptide and peptide hormone that is produced in certain neurons within the central nervous system and peripheral nervous system. It is one of three endorphins that are produced in humans, the others being α-endorphin and γ-endorphin. There are multiple forms of β-endorphin with the full sequence of Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu (31 amino acids) denoted as β-endorphin(1-31) and variants truncated to the first 26 and 27 amino acids as β-endorphin(1-26) and β-endorphin(1-27). However, β-endorphin(1-31) is the only form that possess a potent analgesic effect and it is the primary form located in the anterior pituitary gland, and regions such as the hypothalamus, midbrain, and amygdala. The first 16 amino acids are identical to α-endorphin. β-Endorphin is considered to be a part of the endogenous opioid and endorphin classes of neuropeptides; all of the established endogenous opioid peptides contain the same N-terminal amino acid sequence, Tyr-Gly-Gly-Phe, followed by either -Met or -Leu. Function of β-endorphin has been known to be associated with hunger, thrill, pain, maternal care, sexual behavior, and reward cognition. In the broadest sense, β-endorphin is primarily utilized in the body to reduce stress and maintain homeostasis. In behavioral research, studies have shown that β-endorphin is released via volume transmission into the ventricular system in response to a variety of stimuli, and novel stimuli in particular.
== Use and effects == The drug produces similar autonomic and psychoactive effects as LSD in humans, although its hallucinogenic effects are less pronounced. It has been found to possess about one-sixth to one-eighth (i.e., ~15% overall) of the potency of LSD in inducing mydriasis (pupil dilation) and psychedelic effects, respectively, in humans. More specifically, 2,3-dihydro-LSD is psychedelic at doses of 3.0 to 4.5 μg/kg (210–315 μg for a 70-kg person), while LSD is hallucinogenic at doses of 0.5 to 1.0 μg/kg (35–70 μg for a 70-kg person). In addition to its greatly reduced potency compared to LSD, 2,3-dihydro-LSD has a delayed onset and time to peak effects relative to LSD. The duration of 2,3-dihydro-LSD was roughly 8 to 12 hours and was longer than that of LSD (which had a duration of about 7 hours in the study) as well.
==== mGluR1 and mGluR4 ==== Signal from these two receptors are conveyed in a manner independent of TRPM5. Single umami-sensitive fibres in mice are mostly either "sucrose-best" or "glutamate-best". Within each type there are two subtypes: one shows synergistic activation between monopotassium glutamate and inosine monophosphate, the other does not. The TAS1R1/3 + TRPM5 route uses the "sucrose-best" fibers with synergy, while mGluR1 and mGluR4 use both of the "glutamate-best" subtypes.
Sources: en.wikipedia.org
== Treatment == The major emphasis of the treatment of JIA is helping the child or young person regain normal levels of physical and social functioning by controlling inflammation and extra-articular symptoms. Clinical remission should be the primary target for all people. Prompt recognition and management is important as early initiation of medication therapy increases the likelihood of a response to first-line treatments and low disability. Consensus treatment guidelines exist for the treatment of JIA. Optimal management of JIA requires a multidisciplinary team working to address the needs of an individual child. Optimizing physical and social functioning is accomplished using non-pharmacological strategies such as physical therapies, pain management strategies, and social supports. Medications are used to control inflammation and reduce or prevent extra-articular symptoms.Non-steroidal anti-inflammatory drugs (NSAIDs) are used for symptomatic relief of joint pain in children with JIA. Disease-modifying antirheumatic drugs (DMARDs), which inhibit specific pathways in the inflammation pathways responsible for JIA, are a primary treatment. Lifelong DMARD treatment is often required, and drug-free remission is exceedingly rare. Oligoarticular JIA (which comprises 40-50% of all JIA cases) by definition involves 4 or fewer joints in the first 6 months of the disease. After 6 months, some cases become polyarticular (involving more than 4 joints). This polyarticular subtype is associated with a lower remission rate with medical therapy.
The nitride anion (N3−) is the strongest π donor known among ligands (the second-strongest is O2−). Nitrido complexes are generally made by the thermal decomposition of azides or by deprotonating ammonia, and they usually involve a terminal {≡N}3− group. The linear azide anion (N−3), being isoelectronic with nitrous oxide, carbon dioxide, and cyanate, forms many coordination complexes. Further catenation is rare, although N4−4 (isoelectronic with carbonate and nitrate) is known.
In his public letter of resignation, he cited his reasons as being the lack of "the possibility of fulfilling, with the necessary total transparency, autonomy, and freedom, what Cuban Masonic legislation defines as required to carry out this responsibility." Alfonso Vidal said that the Grand Lodge was in the practice of "distorting Masonic Law." He also noted that because he had signed Decree 634, it was virtually impossible for him to have abandoned his post. He wrote that he was aware that he had been wrongfully terminated through an Extraordinary Session of the Supreme Court of Masonic Justice, and that those who signed his tacit resignation were being ordered to do so by the State Security Unit. He lamented the nature of the "...political gangsterism that works in the Grand Lodge of Cuba." Alfonso Vidal wrote that: "Cuban Masons have the right to know that our institution is under one of the greatest attacks it has received since January 1, 1959." He called back on the events surrounding the case of Grand Commander Viñas Alonso, and the letter that Viñas Alonso had sent to President Díaz-Canel. He said that the situation since Díaz-Canel had sent the State Security Unit after Viñas Alonso, the situation in Cuban Freemasonry had become increasingly difficult to operate within as an ethical and moral Grand Master. He could not fulfill his obligations as Grand Master for the fear of what actions the Cuban state might take against him. He also urged Cuban Freemasons to reject anyone from the Cuban intelligence community to ever again gain high office in the Grand Lodge.
=== Hyperbaric oxygen === In 2015, a Cochrane review concluded that for people with diabetic foot ulcers, hyperbaric oxygen therapy reduced the risk of amputation and may improve the healing at 6 weeks. However, there was no benefit at one year, and the quality of the reviewed trials was inadequate to draw strong conclusions.
BeaverTails pastry (or Queues de Castor pâtisserie in Quebec) is a chain of pastry stands operated by BeaverTails Canada Inc. The chain's namesake product is a line of fried dough pastries, individually hand-stretched to resemble a beaver's tail. The chain began in Ottawa and now has franchises and licensees in six countries: Canada (Atlantic Canada, Ontario, Alberta, Manitoba, British Columbia and Quebec), the United States, Japan, France, U.A.E., and Mexico.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.